I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $267.78M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
Amphora |
Research Triangle Park, N.C. |
9/27 | $25 | Amphora raised $25M with investors Arch Venture Partners, California Public Employees' Retirement System, CW Group, MPM Asset Management, OrbiMed Advisors LLC, Venrock Associates and Versant Ventures |
Athenix | Research Triangle Park, N.C. | 9/11 | $8 | Athenix raised $8M in its first round led by Intersouth Partners and Polaris Venture Partners |
Bio | Ramat Gan, Israel | 9/10 | $7.8 | Bio Information completed its first round of funding for $7.8M; investors were OrbiMed Advisors LLC, Yozma and Fred Frank, the vice chairman of Lehman Brothers |
Cellfactors |
Cambridge, UK |
9/19** |
£2.5 | Cellfactors raised US$3.66M in a private financing |
Cumbre |
Dallas |
9/20 |
$26 |
Cumbre raised $26M in a second round of financing from Pharma Vision AG and Vulcan Inc. |
Entelos |
Menlo Park, Calif. |
9/6 |
$25 |
Entelos raised $25M in a financing round led by Bear Stearns Health Innoventures LP; other investors were Earlybird, equity4life, Compaq Computer Corp., Abingworth Ventures, Boulder Ventures, Charles River Ventures and St. Paul Ventures |
Euro- | Hennigsdorf, Germany | 9/26** | EUR9.5 | EuroProteome completed its second financing round led by Earlybird Venture Capital and Heidelberg Innovation; other investors were Nextech Venture and Aventic Partners |
Locus | Blue Bell, Pa. | 9/7 | $28 | Locus raised $28M in the first closing of its third round; the company has the option to raise an additional $12M as part of a second closing; the financing was led by Wanger Asset Management LP, and included ING Furman Selz Capital Management LLC, INVESCO Global Health Sciences Fund, Delphi Ventures, Johnson & Johnson Development Corp., Tredegar Investments, Prism Venture Partners, Origin Capital, Amerindo Investment Advisers, ReqMed Co. and Cooper Hill Partners LLC |
Macro- | Rockville, Md. | 9/25 | $13.5 | MacroGenics completed the second tranche of its Series A financing, bringing the total raised to $13.5M; investors included InterWest Partners LP and OrbiMed Advisors LLC |
Merix | Durham, N.C. | 9/11 | $39.5 | Merix raised $39.5M in a second round of financing co-led by Sofinov and Techno Venture Management; other investors were ABN Amro Ventures BV, GeneChem Therapeutics Venture Fund LP, Oakwood Medical Investors, Pacific Horizon Partners, Sanders Morris Harris Inc., SHV Ventures, TFG Venture Capital AG & Co. KgaA, Aurora Funds Ventures, BD Ventures, Cordova Ventures, Harbinger/Aurora Ventures, Intersouth Partners, MDS Capital and Senmed Medical Ventures |
NimbleGen | Madison, Wis. | 9/11 | $9 | NimbleGen raised $9M in a private round; investors included Venture Investors Management LLC, the State of Wisconsin Investment Board, Baird Venture Partners, Skyline Ventures, the Wisconsin Alumni Research Foundation and Tactics II Investments LLC |
Protiva | Vancouver, British Columbia | 9/6 | C14.5 | Protiva raised US$9.3M in an equity financing led by MDS Capital |
PTC | South Plainfield, N.J. | 9/20 | $40 | PTC raised $40M in a second round of financing led by CSFB Private Equity, Vulcan Ventures Inc., and Bay City Capital; other investors were CDIB Biotech Inc., China Development Industrial Bank Inc., Delphi Ventures, HealthCap, The Manufacturers Life Insurance Company, NMT New Medical Technologies, Nova A/S and Pictet Global Sector Fund Biotech |
Solexa |
Cambridge, UK |
9/24 |
US$17 |
Solexa raised $17M in a private equity financing round led by Schroeder Ventures Life Sciences; other investors were Oxford Bioscience Partners Boston, Amadeus Capital Partners and founding investor Abingworth Management |
SynGenix |
Cambridge, UK |
9/13 |
£5 | SynGenix completed a US$7.25M private placement co-led by Technomark Medical Ventures and World Life Sciences plc; other investors were Yorkshire Funds Managers Ltd., Providence Investment Co., Generics Asset Management Ltd., Cambridge Research, Innovation Ltd. and the individual Martin Bloom |
Note: | ||||
** Denotes the date the item ran in BioWorld International. | ||||
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $13M |
||||
Company (Symbol)#* |
Partner (Country) | Amt. (M) | Triggering Event | Details (Date) |
Avanir | GlaxoSmithKline Consumer Healthcare (division of GlaxoSmithKline plc; UK) | $5 | Milestone payment | Avanir received the payment relating to its agreement with GlaxoSmithKline on the marketing of Abreva in the U.S. (9/19) |
Cortex | NV Organon (the Netherlands) | $2 | Milestone payment | NV Organon decided to continue development of the Ampakine Org 24448 in a Phase II trial for schizophrenia, triggering the milestone payment (9/18) |
Cubist | Gilead Sciences Inc. | $3 | Milestone payment | Cubist received a $3M milestone payment for completing patient enrollment in Phase III trials of Cidecin (9/6) |
Cyto- | GlaxoSmithKline plc (UK) | $2 | Milestone payment | Cytokinetics earned the milestone payment for GlaxoSmithKline's selection of lead oncology compounds (9/21) |
Human | GlaxoSmithKline plc (UK) | ND | Milestone payment | Human Genome received a milestone payment for initiating Phase I trials with Lp-PLA2 inhibitor (9/6) |
Ligand | TAP Pharmaceutical Products Inc. | $1 | Milestone payment | Ligand earned a milestone for TAP's decision to proceed with devleopment of LGD2226 (9/11) |
Ligand | Eli Lilly and Co. | ND | Milestone payment | Ligand earned a milestone payment as a result of Lilly filing an investigational new drug application with the FDA for LY519818 (9/26) |
Paradigm | Monsanto Co. | ND | Milestone payment | Paradigm reached a milestone in its commercial partnership with Monsanto, and will receive an undisclosed payment (9/26) |
Notes: |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
* Denotes privately held company. |
||||
ND = Not disclosed |
||||
AMEX = American Stock Exchange; NYSE = New York Stock Exchange |
||||
